MNPR
Monopar Therapeutics Inc
NASDAQ: MNPR · HEALTHCARE · BIOTECHNOLOGY
$52.15
+4.05% today
Updated 2026-04-30
Market cap
$361.51M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.85
Dividend yield
—
52W range
$28 – $105
Volume
0.2M
Monopar Therapeutics Inc (MNPR) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-636328.00 | $-1.19M | $-2.63M | $-2.89M | $-3.02M | $-4.66M | $-7.32M | $-7.23M | $-7.86M | $-6.40M | $-12.20B |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | $0.00 | $3.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | $305205.00 | $529332.00 | $1.01M | $1.32M | $1.47M | $1.64M | $1.90M | $1.14M | $4.84B |
| Free cash flow | $-636328.00 | $-1.19M | $-2.63M | $-2.89M | $-3.02M | $-4.66M | $-7.32M | $-7.23M | $-7.86M | $-6.40M | $-12.20B |
| Investing cash flow | — | — | — | — | — | — | — | $-4.92M | $4.93M | $-14.34M | — |
| Financing cash flow | $3.44M | $1.26M | $9.54M | $-206270.00 | $9.35M | $8.18M | $10.88M | $32873.00 | $2.03M | $59.29M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $3.52M | — | — | — | — | — |